COPENHAGEN, Denmark, Jan. 07, 2019 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical aggregation that utilizes its avant-garde TransCon™ technologies to abode cogent unmet medical needs, today alien Eyes 3×3, the company’s cardinal roadmap through 2025 to accomplish acceptable growth, at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco. As allotment of that vision, the aggregation additionally appear oncology as its added absolute ameliorative breadth of focus.
“With the analytic validation of our three endocrinology attenuate ache artefact candidates, we accept congenital a able foundation to authorize Ascendis as a arch attenuate ache company,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Controlling Officer. “Having able the fundamentals of our Eyes 20/20, we are now implementing a new cardinal roadmap through 2025, Eyes 3×3. The ambition is to position Ascendis as a arch biopharma aggregation carrying acceptable advance through assorted approaches.”
He continued, “Today, we are announcement that oncology is our abutting ameliorative focus, an breadth with above unmet medical needs. The cornerstone of our oncology activity action is to administer the aforementioned algorithm for artefact addition that resulted in acknowledged analytic validation of 3 out of 3 artefact candidates in endocrinology attenuate disease.”
Vision 3×3: Acceptable Advance Through Assorted Approaches
The ambition of Ascendis Pharma’s Eyes 3×3 cardinal roadmap through 2025 is to accomplish acceptable advance through assorted approaches:
Endocrinology Attenuate Ache Pipeline: Selected Key Milestones
Ascendis Pharma has three endocrinology attenuate ache artefact candidates in analytic development based on its TransCon technology platform. The aggregation expects anniversary of these three absolute programs to accomplish cogent analytic advance during 2019:
Oncology: A New Ameliorative Breadth with Experienced Leadership
Ascendis additionally appear that it has accustomed oncology as its added absolute ameliorative area. To advance the oncology analysis and development programs, Ascendis afresh appointed Juha Punnonen, MD, PhD, as Senior Vice President and Head of Oncology.
Dr. Punnonen is an experienced scientist, clinician, and biotechnology/pharma controlling with a clue almanac in architecture and managing R&D teams from early-stage analysis to development. He has added than 25 years of acquaintance in the discovery, assuming and development of monoclonal antibodies, nanobodies, baby molecules, cytokines, and immuno-modulatory proteins. Dr. Punnonen was best afresh an Controlling Director, Oncology Analysis Research, at Merck & Co., Inc. breadth he accommodating preclinical analysis and aboriginal development programs for Merck Oncology, including alien analytic collaborations for Merck’s anti-PD-1 antibiotic Keytruda® (pembrolizumab). He has authored 89 accurate publications and 26 issued U.S. patents.
Ascendis Pharma’s oncology analysis is based in the San Francisco Bay Area.
Presentation at J.P. Morgan Healthcare Conference
A alive webcast of the J.P. Morgan presentation and associated Question and Answer affair will be accessible today at 8:00 a.m. Pacific Time in the Investors and News breadth of the Ascendis Pharma website at: https://ascendispharma.gcs-web.com/events-and-presentations/upcoming-events. A webcast epitomize will additionally be accessible for 30 days.
The company’s accumulated presentation, including the slides from J.P. Morgan, will be accessible at the aforementioned articulation afterward admission of the presentation.
About Ascendis Pharma A/S
Ascendis Pharma is applying its avant-garde belvedere technology to body a leading, absolutely chip biopharma aggregation focused on authoritative a allusive aberration in patients’ lives. Guided by its amount ethics of patients, science and passion, the aggregation utilizes its TransCon™ technologies to actualize new and potentially best-in-class therapies.
Ascendis Pharma currently has a activity of three absolute attenuate ache endocrinology artefact candidates in analytic development. Additionally, Ascendis Pharma has multi-product collaborations with Sanofi in diabetes and Genentech in the acreage of ophthalmology and continues to aggrandize into added ameliorative areas for both centralized and alien development.
Ascendis is headquartered in Copenhagen, Denmark, with added offices in Heidelberg, Germany and Palo Alto, California.
For added information, amuse appointment www.ascendispharma.com.
This columnist absolution contains advanced statements that absorb abundant risks and uncertainties. All statements, added than statements of absolute facts, included in this columnist absolution apropos our approaching operations, affairs and objectives of administration are advanced statements. Examples of such statements include, but are not bound to, statements apropos to (i) our ambition to access authoritative approval for our three endocrinology attenuate ache candidates, TransCon hGH, TransCon PTH and TransCon CNP, (ii) our ambition to abound our endocrinology attenuate ache activity by advancing characterization amplification programs, (iii) our ambition to accompany oncology as our added of three absolute ameliorative breadth of focus, (iv) our affairs to absolution top-line abstracts for our appearance 3 heiGHt trial, (v) our affairs to admit our appearance 2 TransCon PTH balloon in patients with HP and our expectations apropos the timing of absolution of the after-effects from such trial, (vi) our affairs to admit our appearance 2 TransCon CNP balloon for the analysis of accouchement with achondroplasia, (vii) our ambition to body an chip bartering business for the endocrinology attenuate ache authorization in North America and baddest European countries, (viii) our adeptness to administer our belvedere technologies to body a leading, absolutely chip biopharma company, (ix) our expectations apropos our adeptness to actualize potentially best-in-class therapies and (x) our artefact pipeline. We may not absolutely accomplish the plans, backpack out the intentions or accommodated the expectations or projections appear in the advanced statements and you should not abode disproportionate assurance on these advanced statements. Absolute after-effects or contest could alter materially from the plans, intentions, expectations and projections appear in the advanced statements. Various important factors could account absolute after-effects or contest to alter materially from the advanced statements that we make, including the following: our adeptness to administer our TransCon technology to the ameliorative breadth of oncology; abrupt assurance or adeptness after-effects in our TransCon hGH, TransCon PTH and TransCon CNP or added development programs; abrupt costs accompanying to the development of TransCon hGH, TransCon PTH and TransCon CNP or added development programs, accepted and authoritative expenses, added analysis and development costs and our business generally; delays in the development of TransCon hGH, TransCon PTH and TransCon CNP or added development programs accompanying to manufacturing, authoritative requirements, acceleration of accommodating application or added abrupt delays; assurance on third affair manufacturers to accumulation abstraction biologic for planned analytic studies; and our adeptness to access added funding, if needed, to abutment our business activities. For a added description of the risks and uncertainties that could account absolute after-effects to alter from those bidding in these advanced statements, as able-bodied as risks apropos to our business in general, see our accepted and approaching letters filed with, or submitted to, the U.S. Securities and Exchange Commission (SEC), including our Annual Report on Anatomy 20-F for the year ended December 31, 2017, which we filed with the SEC on March 28, 2018. Advanced statements do not reflect the abeyant appulse of any approaching in-licensing, collaborations, acquisitions, mergers, dispositions, collective ventures, or investments we may access into or make. We do not accept any obligation to amend any advanced statements, except as appropriate by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the aggregation logo and TransCon are trademarks endemic by the Ascendis Pharma group. ©January 2019 Ascendis Pharma A/S.
Road Map Template Ppt Is Road Map Template Ppt Any Good? Five Ways You Can Be Certain – road map template ppt
| Welcome to be able to my weblog, in this time period I’m going to show you concerning keyword. And from now on, this can be the primary photograph:
How about photograph preceding? can be which awesome???. if you feel thus, I’l m demonstrate several photograph yet again below:
So, if you wish to have the awesome graphics regarding (Road Map Template Ppt Is Road Map Template Ppt Any Good? Five Ways You Can Be Certain), simply click save link to save these images in your pc. There’re prepared for down load, if you appreciate and wish to obtain it, just click save symbol on the page, and it’ll be directly downloaded in your notebook computer.} Lastly if you would like obtain unique and recent image related to (Road Map Template Ppt Is Road Map Template Ppt Any Good? Five Ways You Can Be Certain), please follow us on google plus or save this page, we attempt our best to give you regular up grade with fresh and new graphics. We do hope you like staying here. For some upgrades and recent information about (Road Map Template Ppt Is Road Map Template Ppt Any Good? Five Ways You Can Be Certain) shots, please kindly follow us on twitter, path, Instagram and google plus, or you mark this page on bookmark area, We try to present you up grade periodically with all new and fresh shots, like your searching, and find the right for you.
Thanks for visiting our site, contentabove (Road Map Template Ppt Is Road Map Template Ppt Any Good? Five Ways You Can Be Certain) published . Today we are pleased to announce we have found an extremelyinteresting topicto be reviewed, namely (Road Map Template Ppt Is Road Map Template Ppt Any Good? Five Ways You Can Be Certain) Lots of people looking for specifics of(Road Map Template Ppt Is Road Map Template Ppt Any Good? Five Ways You Can Be Certain) and certainly one of these is you, is not it?